Medarex Announces 2008 Third Quarter Financi...(2008 2007 ...)

(unaudited) (1)

Cash, cash equivalents and marketable

securities - Medarex $388,399 $334,772

Cash and cash equivalents - Celldex - 14,000

Marketable securities - Genmab - 152,000

Other current assets 15,898 29,013

Property, buildings and equipment, net 72,127 79,925

Marketable securities - Genmab non-current 131,704 139,165

Investment in Celldex Therapeutics 4,996 -

Other assets 9,192 10,985

$622,316 $759,860

Current liabilities $66,854 $81,645

Other liabilities 81,191 89,454

Convertible notes 144,949 143,505

Shareholders' equity 329,322 445,256

$622,316 $759,860

(1) Derived from the December 31, 2007 audited financial statements. For

further information, refer to the consolidated financial statements

and footnotes thereto included in Medarex's Annual Report on Form 10-K

for the year ended December 31, 2007.

This press release dated October 30, 2008, contains non-GAAP financial measures. The following table reconciles the non-GAAP financial measures contained in the press release to the most directly comparable financial measures prepared in accordance with GAAP. These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share. Non-GAAP financial measures should be considered in addition to, and n
'/>"/>